欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2019-03-01 不详 MedSci原创

AbbVie今天宣布欧洲药品管理局(EMA)人用医药产品委员会(CHMP) 推荐将SKYRIZI(risankizumab)是一种研究性白细胞介素-23(IL-23)单抗,用于治疗成人患者的中度至重度斑块状银屑病。

AbbVie今天宣布欧洲药品管理局(EMA)人用医药产品委员会(CHMP) 推荐将SKYRIZI(risankizumab),一种研究性白细胞介素-23(IL-23)单抗,用于治疗中度至重度斑块型银屑病成年患者

CHMP的积极意见是基于其III期临床试验的数据,该计划一共评估了2000多名中度至重度斑块状银屑病患者。在四项实验ultIMMA-1,ultIMMa-2,IMMhance和IMMvent均达到其实验终点,与优特克单抗,阿达木单抗和安慰剂相比,risankizumab在第16周和第52周达到显着升高的反应率,和几乎透明的皮肤(每12周给药一次)。

AbbVie副主席兼总裁Michael Severino博士说:"银屑病对患有该疾病的人产生重大的生理、心理和社会负担。我们很高兴CHMP认可risankizumab可以显着减少银屑病的症状并改善患者的生活质量。今年,超过50%接受risankizumab的患者获得了完全清晰的皮肤。这是我们不断追求创新疗法的重要里程碑,这些创新疗法可满足患有严重皮肤病患者的未满足需求。"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-10-12 snf701207
  6. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-03-03 tomyang93
  8. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1014422, encodeId=98eb101442205, content=<a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15499, encryptionId=58ee1549925, topicName=risankizumab)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Sep 03 23:07:32 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755715, encodeId=edb11e5571535, content=<a href='/topic/show?id=ddf8965617' target=_blank style='color:#2F92EE;'>#IL-23单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9656, encryptionId=ddf8965617, topicName=IL-23单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a34037012693, createdName=achengzhao, createdTime=Sun Jan 26 16:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803252, encodeId=cb6b1803252e1, content=<a href='/topic/show?id=57a7e5125ec' target=_blank style='color:#2F92EE;'>#积极评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75125, encryptionId=57a7e5125ec, topicName=积极评价)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqPdWFricgmt6Dde2ptNxJzD6Y9c4cxpXdTo4pNlVPARAnFdKu6nWIPele9icxApTaFgibq0uVlgRiceQ/132, createdBy=4b8c2500026, createdName=ms8435843352634314, createdTime=Wed Mar 06 16:37:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796911, encodeId=1fb51e96911ce, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Sep 28 14:37:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912097, encodeId=8330191209e52, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 12 22:37:00 CST 2019, time=2019-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464190, encodeId=6e4f146419036, content=<a href='/topic/show?id=736f221484a' target=_blank style='color:#2F92EE;'>#中度至重度斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22148, encryptionId=736f221484a, topicName=中度至重度斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d186606178, createdName=lg.zhao, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490376, encodeId=29e314903e67b, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479647, encodeId=0ff614e964777, content=<a href='/topic/show?id=6e0e9655fd' target=_blank style='color:#2F92EE;'>#IL-23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9655, encryptionId=6e0e9655fd, topicName=IL-23)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e8f7562522, createdName=124987a0m68(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479589, encodeId=1c1614e95899d, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sun Mar 03 14:37:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]